Metformin regulates glycemic homeostasis in patients with type 2 diabetes mellitus as an NO donor
https://doi.org/10.14341/2072-0351-816
Abstract
Aim.
To evaluate the influence of metformin on nitric oxide bioavailability in patients with type 2 diabetes mellitus (T2DM) regarding glycemic homeostasis, and to investigate a correlation between metformin dosage and NO levels in vivo.
Materials and Methods.
Two groups ? primary and control ? were assembled for the clinical section of this study. Patients with newly diagnosed T2DM on metformin therapy were included to the primary group, while drug-naive T2DM patients were enrolled as control subjects. Glycemic parameters and NO bioavailability was tested in both groups prior to and after the follow-up period. Experimental section was dedicated to the elucidation of potential dose-dependent effects of metformin on NO bioavailability. Mice were intraperitoneally infused with metformin at 0.5; 1.1; 5.6 mg per subject. Tissue detection of NO was performed with diethyldithiocarbamate (DETC) iron complexes to form mononitrosyl iron compounds (MIC) with paramagnetic properties. Control rodents were intraperitoneally infused with metformin without spin trapping.
Results.
We found nitrite and methaemoglobin (a marker for NO bioavailability) to increase in parallel along with glycemic compensation in the primary but not control group. In vivo rodent models showed linear correlation between accumulation of DETC/MIC and dose of metformin, as well as formation of dinitrosyl iron complexes, known as endogenous NO transporters.
Conclusion.
Our data suggests that metformin benefits glycemic homeostasis in T2DM as an NO donor via formation of dinitrosyl iron complexes.
To evaluate the influence of metformin on nitric oxide bioavailability in patients with type 2 diabetes mellitus (T2DM) regarding glycemic homeostasis, and to investigate a correlation between metformin dosage and NO levels in vivo.
Materials and Methods.
Two groups ? primary and control ? were assembled for the clinical section of this study. Patients with newly diagnosed T2DM on metformin therapy were included to the primary group, while drug-naive T2DM patients were enrolled as control subjects. Glycemic parameters and NO bioavailability was tested in both groups prior to and after the follow-up period. Experimental section was dedicated to the elucidation of potential dose-dependent effects of metformin on NO bioavailability. Mice were intraperitoneally infused with metformin at 0.5; 1.1; 5.6 mg per subject. Tissue detection of NO was performed with diethyldithiocarbamate (DETC) iron complexes to form mononitrosyl iron compounds (MIC) with paramagnetic properties. Control rodents were intraperitoneally infused with metformin without spin trapping.
Results.
We found nitrite and methaemoglobin (a marker for NO bioavailability) to increase in parallel along with glycemic compensation in the primary but not control group. In vivo rodent models showed linear correlation between accumulation of DETC/MIC and dose of metformin, as well as formation of dinitrosyl iron complexes, known as endogenous NO transporters.
Conclusion.
Our data suggests that metformin benefits glycemic homeostasis in T2DM as an NO donor via formation of dinitrosyl iron complexes.
About the Authors
Ivan Sergeevich Kuznetsov
First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
Vladimir Anatol'evich Serezhenkov
Institute of Chemical Physics of Russian Academy of Sciences, Moscow
Russian Federation
Russian Federation
Tatiana Ivanovna Romantsova
First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
Anatoliy Fedorovich Vanin
Institute of Chemical Physics of Russian Academy of Sciences, Moscow
Russian Federation
Russian Federation
References
1. Higaki Y, Hirshman MF, Fujii N, Goodyear LJ. Nitric Oxide Increases Glucose Uptake Through a Mechanism That Is Distinct From the Insulin and Contraction Pathways in Rat Skeletal Muscle. Diabetes. 2001;50(2):241-247. DOI: http://dx.doi.org/10.2337/diabetes.50.2.241
2. Nacci C, Tarquinio M, Montagnani M. Molecular and clinical aspects of endothelial dysfunction in diabetes. Internal and Emergency Medicine. 2009;4(2):107-116. DOI: http://dx.doi.org/10.1007/s11739-009-0234-7
3. Lewandowska H, Brzóska K, Meczyńska-Wielgosz S, Rumianek K, Wójciuk G, Kruszewski M. Dinitrosyl iron complexes--structure and biological functions. Postepy Biochemii. 2010;56(3):298-304.
4. Chazov EI, Rodnenkov OV, Zorin AV, Lakomkin VL, Gramovich VV, Vyborov ON, et al. Hypotensive effect of Oxacom(R) containing a dinitrosyl iron complex with glutathione: animal studies and clinical trials on healthy volunteers. Nitric Oxide. 2012;26(3):148-156. DOI: http://dx.doi.org/10.1016/j.niox.2012.01.008
5. Сереженков ВА, Ванин АФ, Шехтер АБ, Руденко ТГ, ГаврильчакАВ, Пекшев АВ. Динамика уровня эндогенного и экзогенного оксида азота в тканях раны и органах крыс (ЭПР-спектроскопическая оценка). В мат. науч-практ. конф. Под ред. Грачева С.В., Шехтер А.Б., Козлова Н.П. Москва; 2001. Стр. 35-40. [Serezhenkov VA, Vanin AF, Shekhter AB, Rudenko TG, Gavril'chakAV, Pekshev AV. Dinamika urovnya endogennogo i ekzogennogo oksida azota v tkanyakh rany i organakh krys (EPR-spektroskopicheskaya otsenka). Conference proceedings. Ed by Grachev S.V., Shekhter A.B., Kozlov N.P. Moscow; 2001. P. 35-40.]
6. Велиев ЕИ, Котов СВ, Шишло ВК, Сереженков ВА, Лозинский ВИ, Ванин АФ. Влияние динитрозильных комплексов железа с тиолсодержащими лигандами на состояние кавернозных тел пениса у крыс. Биофизика. 2008;53(2):326-335. [Veliev EI, Kotov SV, Shishlo VK, Serezhenkov VA, Vanin AF, Lozinsky VI. Beneficial effect of dinitrosyl iron complexes with thiol ligands on the rat penile cavernous bodies. Biophysics. 2008;53(2):153-157.]
7. D'Autréaux B, Horner O, Oddou J-L, Jeandey C, Gambarelli S, Berthomieu C, et al. Spectroscopic Description of the Two Nitrosyl−Iron Complexes Responsible for Fur Inhibition by Nitric Oxide. Journal of the American Chemical Society. 2004;126(19):6005-6016. DOI: http://dx.doi.org/10.1021/ja031671a
8. Henstridge DC, Drew BG, Formosa MF, Natoli AK, Cameron-Smith D, Duffy SJ, et al. The effect of the nitric oxide donor sodium nitroprusside on glucose uptake in human primary skeletal muscle cells. Nitric Oxide. 2009;21(2):126-131. DOI http://dx.doi.org/10.1016/j.niox.2009.06.002
9. Paolisso G, Tagliamonte MR, Marfella R, Verrazzo G, D'Onofrio F, Giugliano D. L - arginine but not D-arginine stimulates insulin-mediated glucoseuptake. Metabolism. 1997;46(9):1068-1073. DOI: http://dx.doi.org/10.1016/j.niox.2009.06.002
10. Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Галстян ГР, Майоров ПЮ, Мкртумян АМ, Петунина НА, Сухарева ОЮ. Консенсус совета экспертов Российской Ассоциации Эндокринологов по инициации и интенсификации сахароснижающей терапии больных сахарным диабетом 2типа. Сахарный диабет. 2011;(4):6-17. [Dedov I.I., Shestakova M.V., Ametov A.S., Antsiferov M.B., Galstyan G.R., Mayorov A.Yu., Mkrtumyan A.M., Petunina N.F., Sukhareva O.Yu. Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapy in type 2 diabetes mellitus. Diabetes mellitus. 2011;(4):6-17.] [Epub]
11. Сереженков ВА, Кузнецов ИС, Романцова ТИ, Кузнецова МИ, Ванин АФ. Антидиабетический препарат «метформин» - донор оксида азота: ЭПР-спектроскопическая оценка эффективности действия «метформина». Биофизика. 2011;56(6):1125-1133. [Serezhenkov VA, Kuznetsov IS, Romantsova TI, Kuznetsova MI, Vanin AF. Antidiabetes drug metformin is a donor of nitric oxide: ESR measurement of efficiency. Biophysics. 2011;56(6):1125-1133.]
12. Кузнецов ИС, Сереженков ВА, Ванин АФ, Романцова ТИ. Влияние метформина на биодоступность оксида азота у пациентов с сахарным диабетом 2 типа. Ожирение и метаболизм. 2012;(1):29-33. [Kuznetsov IS, Serezhenkov VA, Vanin AF, Romantsova TI. Effect of metformin on the bioavailability of nitric oxide in patients with type 2 diabetes. Obesity and metabolism. 2012;(1):29-33.]
Review
For citations:
Kuznetsov I.S., Serezhenkov V.A., Romantsova T.I., Vanin A.F. Metformin regulates glycemic homeostasis in patients with type 2 diabetes mellitus as an NO donor. Diabetes mellitus. 2013;16(3):41-45. (In Russ.) https://doi.org/10.14341/2072-0351-816
Views:
744
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
